JP6005656B2 - ベンゾイミダゾール呼吸合胞体ウイルス阻害剤 - Google Patents

ベンゾイミダゾール呼吸合胞体ウイルス阻害剤 Download PDF

Info

Publication number
JP6005656B2
JP6005656B2 JP2013543799A JP2013543799A JP6005656B2 JP 6005656 B2 JP6005656 B2 JP 6005656B2 JP 2013543799 A JP2013543799 A JP 2013543799A JP 2013543799 A JP2013543799 A JP 2013543799A JP 6005656 B2 JP6005656 B2 JP 6005656B2
Authority
JP
Japan
Prior art keywords
compound
compound according
compounds
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013543799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545785A (ja
JP2013545785A5 (OSRAM
Inventor
コーイマン，ルートビヒ・ポール
ドマン，サミユエル・ドミニク
フー，リリ
ヨンカース，テイム・ヒユーゴ・マリア
ラボワソン，ピエール・ジヤン−マリー・ベルナール
ターリ，アブデラー
バンドビル，サンドリーヌ・マリー・エレーヌ
Original Assignee
ヤンセン・サイエンシズ・アイルランド・ユーシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6005656(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン・サイエンシズ・アイルランド・ユーシー filed Critical ヤンセン・サイエンシズ・アイルランド・ユーシー
Publication of JP2013545785A publication Critical patent/JP2013545785A/ja
Publication of JP2013545785A5 publication Critical patent/JP2013545785A5/ja
Application granted granted Critical
Publication of JP6005656B2 publication Critical patent/JP6005656B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013543799A 2010-12-16 2011-12-16 ベンゾイミダゾール呼吸合胞体ウイルス阻害剤 Expired - Fee Related JP6005656B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10195467 2010-12-16
EP10195467.5 2010-12-16
PCT/EP2011/073008 WO2012080446A1 (en) 2010-12-16 2011-12-16 Benzimidazole respiratory syncytial virus inhibitors

Publications (3)

Publication Number Publication Date
JP2013545785A JP2013545785A (ja) 2013-12-26
JP2013545785A5 JP2013545785A5 (OSRAM) 2014-06-26
JP6005656B2 true JP6005656B2 (ja) 2016-10-12

Family

ID=43875271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543799A Expired - Fee Related JP6005656B2 (ja) 2010-12-16 2011-12-16 ベンゾイミダゾール呼吸合胞体ウイルス阻害剤

Country Status (30)

Country Link
US (1) US8865705B2 (OSRAM)
EP (1) EP2651903B1 (OSRAM)
JP (1) JP6005656B2 (OSRAM)
KR (1) KR101876240B1 (OSRAM)
CN (2) CN107417683A (OSRAM)
AR (1) AR085203A1 (OSRAM)
AU (1) AU2011343255B2 (OSRAM)
BR (1) BR112013012137A2 (OSRAM)
CA (1) CA2821999C (OSRAM)
CL (1) CL2013001713A1 (OSRAM)
CY (1) CY1117751T1 (OSRAM)
DK (1) DK2651903T3 (OSRAM)
EA (1) EA022972B1 (OSRAM)
ES (1) ES2576180T3 (OSRAM)
HK (1) HK1247616A1 (OSRAM)
HR (1) HRP20160650T1 (OSRAM)
HU (1) HUE029247T2 (OSRAM)
IL (1) IL225640A (OSRAM)
MX (1) MX340030B (OSRAM)
MY (1) MY156641A (OSRAM)
NZ (1) NZ609450A (OSRAM)
PH (1) PH12013500796A1 (OSRAM)
PL (1) PL2651903T3 (OSRAM)
PT (1) PT2651903E (OSRAM)
SG (1) SG190766A1 (OSRAM)
SI (1) SI2651903T1 (OSRAM)
TW (1) TWI530495B (OSRAM)
UA (1) UA112298C2 (OSRAM)
WO (1) WO2012080446A1 (OSRAM)
ZA (1) ZA201304424B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI515187B (zh) * 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI541241B (zh) * 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) * 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
US20150111868A1 (en) 2012-06-15 2015-04-23 Jansen R&D Ireland Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
WO2013186334A1 (en) * 2012-06-15 2013-12-19 Janssen R&D Ireland 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
WO2014009302A1 (en) * 2012-07-10 2014-01-16 F. Hoffmann-La Roche Ag Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection
BR112015008325B1 (pt) 2012-10-16 2022-01-25 Janssen Sciences Ireland Uc Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende
US10081618B2 (en) 2013-01-28 2018-09-25 Janssen Sciences Ireland Uc Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus ativiral agents
CN105392787B (zh) * 2013-05-14 2017-11-24 豪夫迈·罗氏有限公司 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚
MX2015015691A (es) 2013-05-14 2016-03-04 Hoffmann La Roche Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion del virus sincital respiratorio.
JP6262347B2 (ja) * 2013-08-15 2018-01-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 呼吸器合胞体ウイルス感染症の処置および予防のための新規アザ−オキソ−インドール
CN114716426A (zh) 2013-08-21 2022-07-08 詹森生物制药有限公司 抗病毒化合物
WO2015065336A1 (en) * 2013-10-29 2015-05-07 Medivir Ab Respiratory syncytial virus inhibitors
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
WO2016022464A1 (en) * 2014-08-05 2016-02-11 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
CN108200760B (zh) 2015-07-22 2022-04-01 英安塔制药有限公司 作为rsv抑制剂的苯并二氮杂䓬衍生物
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
EP3582784B1 (en) 2017-02-16 2022-06-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
AU2018339068B2 (en) 2017-09-29 2022-12-15 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
MX394621B (es) 2017-11-13 2025-03-24 Enanta Pharm Inc Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona
PH12021552201A1 (en) 2019-03-18 2022-05-30 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2022003984A (es) 2019-10-04 2022-07-27 Enanta Pharm Inc Compuestos heterociclicos antivirales.
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2021250180A1 (en) 2020-06-11 2021-12-16 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US11945830B2 (en) 2021-02-26 2024-04-02 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001428A1 (en) 1996-07-08 1998-01-15 Du Pont Pharmaceuticals Company AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN
WO2000020400A1 (en) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
PT1196408E (pt) 1999-06-28 2005-01-31 Janssen Pharmaceutica Nv Inibidores da replicacao do virus sincicial respiratorio
TR200103806T2 (tr) 1999-06-28 2002-06-21 Janssen Pharmaceutica N. V. Solunum sistemi sinsitiyal virüsünün replikasyonunu inhibe edici maddeler.
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
US6489338B2 (en) 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6506738B1 (en) 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
US20040166137A1 (en) 2002-11-08 2004-08-26 Lackey John William Hetero-substituted benzimidazole compounds and antiviral uses thereof
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類

Also Published As

Publication number Publication date
PL2651903T3 (pl) 2016-10-31
CY1117751T1 (el) 2017-05-17
NZ609450A (en) 2014-10-31
WO2012080446A1 (en) 2012-06-21
DK2651903T3 (da) 2016-06-27
UA112298C2 (uk) 2016-08-25
CA2821999A1 (en) 2012-06-21
CN103313974A (zh) 2013-09-18
BR112013012137A2 (pt) 2016-08-16
EA022972B1 (ru) 2016-03-31
JP2013545785A (ja) 2013-12-26
CN107417683A (zh) 2017-12-01
PT2651903E (pt) 2016-06-17
MY156641A (en) 2016-03-15
PH12013500796A1 (en) 2013-06-24
EP2651903B1 (en) 2016-03-23
KR101876240B1 (ko) 2018-08-02
HUE029247T2 (en) 2017-02-28
CL2013001713A1 (es) 2013-10-11
AU2011343255B2 (en) 2014-12-11
MX2013006886A (es) 2013-07-05
KR20140025321A (ko) 2014-03-04
CA2821999C (en) 2019-02-26
SI2651903T1 (sl) 2016-07-29
IL225640A (en) 2015-02-26
AR085203A1 (es) 2013-09-18
TWI530495B (zh) 2016-04-21
US8865705B2 (en) 2014-10-21
ES2576180T3 (es) 2016-07-06
SG190766A1 (en) 2013-07-31
MX340030B (es) 2016-06-21
EA201390888A1 (ru) 2013-12-30
HRP20160650T1 (hr) 2016-07-15
EP2651903A1 (en) 2013-10-23
TW201305142A (zh) 2013-02-01
AU2011343255A1 (en) 2013-05-02
ZA201304424B (en) 2014-12-23
IL225640A0 (en) 2013-06-27
HK1247616A1 (zh) 2018-09-28
US20130267508A1 (en) 2013-10-10

Similar Documents

Publication Publication Date Title
JP6005656B2 (ja) ベンゾイミダゾール呼吸合胞体ウイルス阻害剤
TWI515187B (zh) 作為呼吸道融合病毒抗病毒劑之吲哚類
JP5876501B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのアザベンゾイミダゾール
JP5876502B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのアザインドール
JP5876503B2 (ja) 呼吸合胞体ウイルスの抗ウイルス剤としてのイミダゾピリジン
JP6383735B2 (ja) Ｒｓウイルスの抗ウイルス剤としてのキノキサリノンおよびジヒドロキノキサリノン
JP2015523350A (ja) Ｒｓウイルス抗ウイルス薬としての、ベンゾイミダゾールによって置換された新規１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
EP2864323B1 (en) 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
JP2015519385A (ja) Ｒｓウイルス抗ウイルス薬としての、ベンゾイミダゾールによって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
JP2015519387A (ja) Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
HK1185065A (en) Benzimidazole respiratory syncytial virus inhibitors
HK1185613B (en) Indoles as respiratory syncytial virus antiviral agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141215

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150617

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160810

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160907

R150 Certificate of patent or registration of utility model

Ref document number: 6005656

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees